{"id":"matching-placebo-to-sita-met-fdc","safety":{"commonSideEffects":[{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sita/Met FDC works by inhibiting the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones, thereby increasing the levels of incretin hormones and enhancing the release of insulin in response to meals. Metformin, on the other hand, decreases glucose production in the liver and increases insulin sensitivity.","oneSentence":"Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:18.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo to Sita/Met FDC","genericName":"Matching Placebo to Sita/Met FDC","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}